Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
Key Takeaways: GLP-1 medications are driving rising demand and costs for health plans Insurers face pressure to balance access, cost control, and clinical benefits Inefficient prior authorization processes lead to overspending and delays Automation through Agadias PAHub streamlines reviews and improves turnaround times Smarter prior authorization tools help payers manage GLP-1 growth sustainably Navigating the Cost and Access Challenges of GLP-1 Drugs Health plans and other healthcare organizations face the challenge of balancing the long-term clinical benefits of GLP 1 medications with their immediate financial impact
This can best be accomplished by administering it intravenously (IV therapy), thereby bypassing the digestive tract and efficiently delivering it to target tissues
Fluid retention, constipation, menstrual cycle changes, salty meals, travel, stress and different weighing conditions can hide fat loss for days or weeks
: JAMA Psychiatry study highlights (semaglutide in schizophrenia spectrum disorders): Studied adults with schizophrenia spectrum disorders treated with clozapine or olanzapine, two antipsychotics strongly linked to weight gain and metabolic syndrome Participants were randomized to receive semaglutide (GLP-1 receptor agonist) vs placebo, in addition to usual psychiatric care Significant weight loss was observed in the semaglutide group compared with placebo Improved glycemic control including reductions in HbA1c and fasting glucose, even in early metabolic dysregulation Beneficial effects seen early, suggesting potential for prevention of diabetes rather than late treatment Semaglutide was generally well tolerated, with no worsening of psychotic symptoms Addresses a major unmet need, people with serious mental illness die earlier largely due to cardiometabolic disease Supports the role of GLP-1 receptor agonists as an adjunct treatment to mitigate antipsychotic-induced metabolic harm Bottom line: A promising strategy to reduce weight, diabetes risk, and long-term cardiovascular mortality in patients on high-risk antipsychotics
